While artificial intelligence has significantly accelerated the discovery phase of drug development, the financial systems supporting these projects remain stuck in a loop of manual reconciliation. Teams often spend days extracting data from ERPs, clinical trial management systems, and spreadsheets to explain budget variances or enrollment delays. This latency creates operational risks, such as the continued funding of underperforming sites or the late discovery of costly change orders.

Condor’s new agent utilizes a proprietary knowledge graph and a deterministic math layer to provide immediate, actionable answers to complex financial queries. Rather than offering generic forecasting, the tool is tuned to specific R&D workflows. Users can query the platform to determine the cost-to-complete a trial or identify which specific sites are driving budget overruns, allowing the software to build updated models instantly. According to CEO Jen Kyle, the goal is to shift the industry's focus from labor-intensive data hunting to rapid, evidence-based management. The agent operates as part of the broader Condor AI Workflows suite, which is already used by firms like Acadia Pharmaceuticals and BridgeBio Pharma to centralize clinical and financial context.